Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals

Tuberculosis and Respiratory Diseases

Volumn 69, Issue 2, 2010, Pages 95-102

  Park, Jin Kyeong ^a   Koh, Won Jung ^b   Kim, Deog Kyeom ^b   Kim, Eun Kyung ^b   Kim, Yu Il ^b   Kim, Hee Jin ^b   Kim, Tae Hyung ^b   Kim, Jae Yeol ^b   Park, Moo Suk ^b   Park, I Nae ^b   Park, Jae Seuk ^b   Lee, Ki Man ^b   Song, Sook Hee ^b   Lee, Jin Hwa ^b,c   Lee, Seung Heon ^b   Lee, Hyuk Pyo ^b   Yim, Jae Joon ^b   Lim, Jaemin ^b   Jegal, Yang Jin ^b   Jung, Ki Hwan ^b   Huh, Jin Won ^b   Choi, Jae Choi ^b   Shim, Tae Sun ^a,b   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Korean Academy of Tuberculosis and Respiratory Diseases   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Extensively drug resistant tuberculosis; Hospitals, private; Korea; Tuberculosis, multidrug resistant

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; P AMINOSALICYCLIC ACID; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; ROXITHROMYCIN; SALICYLIC ACID; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956675840     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2010.69.2.95     Document Type: Article

References (17)

1. Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E, et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001-2005. Tuberc Respir Dis 2008;64:187-93.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2008.
3. Caminero JA; World Health Organization; American Thoracic Society; British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-37.
4. Korea Center for Disease Control and Prevention, Korean Institute of Tuberculosis. Annual report on the notified tuberculosis patients in Korea. Seoul: Korea Center for Disease Control and Prevention; 2005.
5. Koh WJ, Kwon OJ, Kim CH, Ann YM, Lim SY, Yun JW, et al. Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis at a private general hospital. Tuberc Respir Dis 2003;55:154-64.
6. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82.
7. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;81:430-2.
8. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-5. (Pubitemid 40826156)
9. Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Facchini A, Guenther G, et al. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J 2009;34:778-9.
10. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-9.
11. Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2004;128:523-8.
12. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5.
13. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502.
14. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 2008;15:1956-67.
15. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
16. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-91.
17. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.